Patient Characteristics
ALL
ACUTE LYMPHOBLASTIC LEUKEMIA, LYMPHOBLASTIC LYMPHOMA, ONCOLOGY, ADENOID CYSTIC CARCINOMA
From December 2017 to January 2022, a total of 79 patients enrolled to the study, including 64 subjects to 12 escalating dose cohorts (ranging from 13 mg once daily to 500 mg twice daily 5 days on and 2 days off each week), and 15 subjects to a single confirmatory cohort dosed at 500 mg once daily (Patient demographicsAbbreviations: ACC = adenoid cystic carcinoma, ALL = acute lymphoblastic leukemia, LBL = lymphoblastic lymphoma, ECOG = Eastern Cooperative Oncology Group, y = years.


